复方斑蝥注射液辅助结直肠癌根治术治疗结直肠癌的效果及安全性分析
|
摘要
目的:分析复方斑蝥注射液辅助结直肠癌根治术治疗结直肠癌的效果及安全性分析。方法:选取行结直肠癌根治术的患者82例,根据治疗方法不同分为对照组和观察组。对照组患者术后1个月行单纯化疗治疗,观察组患者术后1个月采用复方斑蝥注射液辅助化疗治疗,分析两组患者治疗后的临床效果。结果:观察组患者总有效率为43.90%,对照组为29.27%,观察组患者总有效率高于对照组,但组间比较差异无统计学意义(P>0.05)。治疗前,两组患者TGF-β1、VEGF水平比较,差异无统计学意义(P>0.05)。治疗2周、4周后,观察组患者TGF-β1、VEGF水平低于对照组,差异有统计学意义(P<0.05)。观察组患者恶心呕吐、神经毒性、骨髓抑制、脱发的发生率低于对照组,腹泻、肝酶异常的发生率与对照组比较,差异无统计学意义(P>0.05)。观察组患者1年、3年复发率分别为0.00%,4.88%;对照组为2.44%,24.39%;观察组3年复发率低于对照组,但1年复发率与对照组比较,差异无统计学意义(P>0.05)。结论:结直肠癌根治术后采用复方斑蝥注射液辅助治疗效果显著,可降低患者TGF-β1、VEGF水平,减少不良反应和复发的发生率,安全性高。
Objective: To analyze the effect of Compound Cantharidin Injection on the reduction of recurrence rate and adverse reaction rate after radical resection of colorectal cancer. Methods:A total of 82 patients undergoing radical resection of colorectal cancer were divided into control group and observation group according to different treatment methods. The patients in the control group were treated with chemotherapy only one month after operation, and those in the observation group were treated with the adjuvant chemotherapy of Compound Cantharidin Injection one month after operation. The clinical effects of the two groups were analyzed. Results:The total effective rate of the observation group was 43.90% and that of the control group was 29.27%. The total effective rate of the observation group was higher than that of the control group, but there was no significant difference between the two groups(P>0.05). Before treatment, there was no significant difference in the levels of TGF-β1 or VEGF between the two groups(P>0.05). After 2 and 4 weeks treatment, the levels of TGF-β1 and VEGF in the observation group were significantly lower than that in the control group(P<0.05). The incidence of nausea and vomiting, neurotoxicity, bone marrow depression and alopecia in the observation group were lower than those in the control group. There was no significant difference between the control group and the control group(P>0.05). The recurrence rate was 0.00% and 4.88% respectively after 1 and 3 yearts in the observation group and that was 2.44% and 24.39% respectively in the control group. The 3-year recurrence rate in the observation group was lower than that in the control group, but there was no significant difference between the observation group and the control group(P>0.05). Conclusion:The adjuvant effect of Compound Cantharidin Injection after radical resection of colorectal cancer was significant, which could reduce the levels of TGF-β1 and VEGF, reduce the incidence of adverse reaction and recurrence, and has high safety.
Objective: To analyze the effect of Compound Cantharidin Injection on the reduction of recurrence rate and adverse reaction rate after radical resection of colorectal cancer. Methods:A total of 82 patients undergoing radical resection of colorectal cancer were divided into control group and observation group according to different treatment methods. The patients in the control group were treated with chemotherapy only one month after operation, and those in the observation group were treated with the adjuvant chemotherapy of Compound Cantharidin Injection one month after operation. The clinical effects of the two groups were analyzed. Results:The total effective rate of the observation group was 43.90% and that of the control group was 29.27%. The total effective rate of the observation group was higher than that of the control group, but there was no significant difference between the two groups(P>0.05). Before treatment, there was no significant difference in the levels of TGF-β1 or VEGF between the two groups(P>0.05). After 2 and 4 weeks treatment, the levels of TGF-β1 and VEGF in the observation group were significantly lower than that in the control group(P<0.05). The incidence of nausea and vomiting, neurotoxicity, bone marrow depression and alopecia in the observation group were lower than those in the control group. There was no significant difference between the control group and the control group(P>0.05). The recurrence rate was 0.00% and 4.88% respectively after 1 and 3 yearts in the observation group and that was 2.44% and 24.39% respectively in the control group. The 3-year recurrence rate in the observation group was lower than that in the control group, but there was no significant difference between the observation group and the control group(P>0.05). Conclusion:The adjuvant effect of Compound Cantharidin Injection after radical resection of colorectal cancer was significant, which could reduce the levels of TGF-β1 and VEGF, reduce the incidence of adverse reaction and recurrence, and has high safety.
引文
[1] 丘嘉煌,李燕,李科,等.广州市2004-2013年结直肠癌发病趋势分析[J].广东医学,2016,37(22):3334-3337.
[2] 周德全,徐亮.腹腔镜与开腹结直肠癌切除术远期生存率和并发症的Meta分析[J].实用医学杂志,2016,32(2):291-294.
[3] 陈艳,朱为民,周冬霞,等.斑蝥酸钠维生素B6联合雷替曲塞和奥沙利铂治疗晚期结直肠癌的临床研究[J].现代药物与临床,2016,31(11):1784-1787.
[4] 刘冰心,唐世锋,李有杰,等.复方斑蝥注射液对中晚期结直肠癌TGF-β1表达影响的前瞻性临床研究[J].云南中医学院学报,2016,39(4):47-50.
[5] 姚宏伟,吴鸿伟,刘荫华.美国癌症联合委员会第八版结直肠癌分期更新及其“预后和预测”评价体系[J].中华胃肠外科杂志,2017,20(1):24-27.
[6] 卫生部医政司,结直肠癌诊疗规范专家工作组.结直肠诊疗规范[J].中华胃肠外科杂志,2010,13(11):865-875.
[7] Sugimoto T,Kiyochi H,Hosoda Y,et al.Two-Stage Radical Resection of a Case of Colon Cancer with Abdominal Wall Invasion and Cholangiocarcinoma[J].Gan to Kagaku Ryoho Cancer & Chemotherapy,2018,45(4):718-720.
[8] 姚嵋方,李风云,刘志,等.FOLFOX4方案联合益气健脾汤治疗结直肠癌的临床研究[J].中国临床药理学杂志,2016,32(18):1663-1665,1669.
[9] 黄芳,刘超英.FOLFOX4方案与XELOX方案治疗转移性结直肠癌的疗效与不良反应分析[J].实用癌症杂志,2016,31(10):1675-1677.
[10] 雷海龙.中药结合FOLFOX4方案对术后结直肠癌患者治疗实效性探讨[J].中国现代医生,2016,54(4):61-64.
[11] 郑重.鸦胆子油对FOLFOX4方案化疗结直肠癌患者细胞免疫功能的影响[J].中国中医药科技,2016,23(6):704-705.
[12] 虞晓林,蒙荣钦,李文中,等.苦参注射液联合FOLFOX4方案对结直肠癌术后疗效的影响[J].实用临床医药杂志,2016,20(7):55-57.
[13] 闫晓红,刘尧,董龙科,等.靶向分子药物联合FOLFOX4治疗转移性结直肠癌的疗效分析[J].广西医科大学学报,2018,35(1):91-93.
[14] 黄臻.黄白抑瘤方联合FOLFOX4化疗对结直肠癌患者术后效果及细胞免疫水平的影响[J].现代中西医结合杂志,2017,26(27):3017-3019.
[15] 王本军,白克运,李云霞,等.结直肠癌患者术后服用十全大补汤联合化疗对血清TGF-β1水平的影响[J].山东医药,2017,57(10):42-44.
[16] 谢泽新,王金烁,刘延冰,等.观察斑蝥酸钠维生素B6注射液联合化疗治疗晚期胃癌的近期疗效和不良反应[J].河北医药,2016,38(10):1554-1556,1559.
[17] 张霞,关洪全.斑蝥酸钠诱导RTP801表达促进结肠癌细胞HCT116凋亡[J].中国医科大学学报,2016,45(3):222-226.
[18] 张彤,何文婷,杨宇飞,等.中医药治疗Ⅳ期结直肠癌中医证候及用药规律文献研究[J].中医杂志,2017,58(11):966-970.
[19] 顾亚红,李明.复方斑蝥胶囊联合卡培他滨、伊立替康治疗结直肠癌患者的疗效观察[J].医学临床研究,2018,35(1):181-183.
[20] Patrono D,Paraluppi G,Romagnoli R.Disease-free survival after radical resection followed by adjuvant chemotherapy for primary hepatic synovial sarcoma[J].Updates in Surgery,2018(Suppl 3):1-3.
[21] 成龙,李沁芸,张燕,等.抗VEGF与抗EGFR靶向药物联合化疗一线治疗转移结直肠癌Meta分析[J].中华肿瘤防治杂志,2017,24(14):1008-1016.
[22] 秦惠萍.血清VEGF和MMP-2检测在结直肠癌诊断中的临床意义[J].检验医学,2016,31(11):967-968.
[2] 周德全,徐亮.腹腔镜与开腹结直肠癌切除术远期生存率和并发症的Meta分析[J].实用医学杂志,2016,32(2):291-294.
[3] 陈艳,朱为民,周冬霞,等.斑蝥酸钠维生素B6联合雷替曲塞和奥沙利铂治疗晚期结直肠癌的临床研究[J].现代药物与临床,2016,31(11):1784-1787.
[4] 刘冰心,唐世锋,李有杰,等.复方斑蝥注射液对中晚期结直肠癌TGF-β1表达影响的前瞻性临床研究[J].云南中医学院学报,2016,39(4):47-50.
[5] 姚宏伟,吴鸿伟,刘荫华.美国癌症联合委员会第八版结直肠癌分期更新及其“预后和预测”评价体系[J].中华胃肠外科杂志,2017,20(1):24-27.
[6] 卫生部医政司,结直肠癌诊疗规范专家工作组.结直肠诊疗规范[J].中华胃肠外科杂志,2010,13(11):865-875.
[7] Sugimoto T,Kiyochi H,Hosoda Y,et al.Two-Stage Radical Resection of a Case of Colon Cancer with Abdominal Wall Invasion and Cholangiocarcinoma[J].Gan to Kagaku Ryoho Cancer & Chemotherapy,2018,45(4):718-720.
[8] 姚嵋方,李风云,刘志,等.FOLFOX4方案联合益气健脾汤治疗结直肠癌的临床研究[J].中国临床药理学杂志,2016,32(18):1663-1665,1669.
[9] 黄芳,刘超英.FOLFOX4方案与XELOX方案治疗转移性结直肠癌的疗效与不良反应分析[J].实用癌症杂志,2016,31(10):1675-1677.
[10] 雷海龙.中药结合FOLFOX4方案对术后结直肠癌患者治疗实效性探讨[J].中国现代医生,2016,54(4):61-64.
[11] 郑重.鸦胆子油对FOLFOX4方案化疗结直肠癌患者细胞免疫功能的影响[J].中国中医药科技,2016,23(6):704-705.
[12] 虞晓林,蒙荣钦,李文中,等.苦参注射液联合FOLFOX4方案对结直肠癌术后疗效的影响[J].实用临床医药杂志,2016,20(7):55-57.
[13] 闫晓红,刘尧,董龙科,等.靶向分子药物联合FOLFOX4治疗转移性结直肠癌的疗效分析[J].广西医科大学学报,2018,35(1):91-93.
[14] 黄臻.黄白抑瘤方联合FOLFOX4化疗对结直肠癌患者术后效果及细胞免疫水平的影响[J].现代中西医结合杂志,2017,26(27):3017-3019.
[15] 王本军,白克运,李云霞,等.结直肠癌患者术后服用十全大补汤联合化疗对血清TGF-β1水平的影响[J].山东医药,2017,57(10):42-44.
[16] 谢泽新,王金烁,刘延冰,等.观察斑蝥酸钠维生素B6注射液联合化疗治疗晚期胃癌的近期疗效和不良反应[J].河北医药,2016,38(10):1554-1556,1559.
[17] 张霞,关洪全.斑蝥酸钠诱导RTP801表达促进结肠癌细胞HCT116凋亡[J].中国医科大学学报,2016,45(3):222-226.
[18] 张彤,何文婷,杨宇飞,等.中医药治疗Ⅳ期结直肠癌中医证候及用药规律文献研究[J].中医杂志,2017,58(11):966-970.
[19] 顾亚红,李明.复方斑蝥胶囊联合卡培他滨、伊立替康治疗结直肠癌患者的疗效观察[J].医学临床研究,2018,35(1):181-183.
[20] Patrono D,Paraluppi G,Romagnoli R.Disease-free survival after radical resection followed by adjuvant chemotherapy for primary hepatic synovial sarcoma[J].Updates in Surgery,2018(Suppl 3):1-3.
[21] 成龙,李沁芸,张燕,等.抗VEGF与抗EGFR靶向药物联合化疗一线治疗转移结直肠癌Meta分析[J].中华肿瘤防治杂志,2017,24(14):1008-1016.
[22] 秦惠萍.血清VEGF和MMP-2检测在结直肠癌诊断中的临床意义[J].检验医学,2016,31(11):967-968.